TABLE OF CONTENTS
1 INTRODUCTION 120
1.1 OBJECTIVES OF THE STUDY 120
1.2 MARKET DEFINITION 120
1.3 OVERVIEW OF THE GLOBAL ANTIVIRAL DRUGS MARKET 120
1.4 LIMITATIONS 122
1.5 MARKETS COVERED 122
2 MARKET SEGMENTATION 128
2.1 MARKETS COVERED 128
2.2 GEOGRAPHICAL SCOPE 129
2.3 YEARS CONSIDERED FOR THE STUDY 130
2.4 CURRENCY AND PRICING 130
2.5 DBMR TRIPOD DATA VALIDATION MODEL 131
2.6 MULTIVARIATE MODELLING 134
2.7 PRODUCT TYPE LIFELINE CURVE 134
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 135
2.9 DBMR MARKET POSITION GRID 136
2.10 MARKET TESTING TYPE COVERAGE GRID 137
2.11 VENDOR SHARE ANALYSIS 138
2.12 SECONDARY SOURCES 139
2.13 ASSUMPTIONS 139
3 EXECUTIVE SUMMARY 140
4 PREMIUM INSIGHTS 143
4.1 PORTERS FIVE FORCES 146
4.2 PESTEL ANALYSIS 147
5 EPIDEMIOLOGY 148
6 PIPELINE ANALYSIS FOR GLOBAL ANTIVIRAL DRUGS MARKET 149
7 REGULATORY FRAMEWORK 150
8 MARKET OVERVIEW 152
8.1 DRIVERS 154
8.1.1 RISING PREVALENCE OF VIRAL INFECTIONS 154
8.1.2 ADVANCEMENTS IN NEW ANTIVIRAL DRUG DEVELOPMENT 154
8.1.3 GROWING DEMAND FOR COMBINATION THERAPIES 156
8.1.4 INCREASING GOVERNMENT FUNDING AND R&D ACTIVITIES 156
8.2 RESTRAINS 157
8.2.1 HIGH COST OF ANTIVIRAL DRUGS 157
8.2.2 EMERGENCE OF DRUG-RESISTANT STRAINS OF VIRUSES 157
8.3 OPPORTUNITIES 158
8.3.1 INCREASING COLLABORATION AND PARTNERSHIP AMONG KEY PLAYERS 158
8.3.2 RISING NOVEL DRUG DELIVERY SYSTEMS 158
8.3.3 DEVELOPMENT OF PERSONALIZED MEDICINES 159
8.4 CHALLENGES 160
8.4.1 PATENT EXPIRATION OF ANTIVIRAL DRUGS 160
8.4.2 DEMAND FOR ALTERNATIVE MEDICINES 161
9 GLOBAL ANTIVIRAL DRUGS MARKET, BY INDICATION 162
9.1 OVERVIEW 163
9.2 INFLUENZA 166
9.2.1 NEURAMINIDASE INHIBITORS 167
9.2.1.1 OSELTAMIVIR 167
9.2.1.2 ZANAMIVIR 167
9.2.1.3 PERAMIVIR 167
9.2.1.4 LANINAMIVIR 167
9.2.2 M2 INHIBITORS 168
9.2.2.1 RIMANTADINE 168
9.2.2.2 OTHERS 168
9.2.3 RNA POLYMERASE INHIBITORS 168
9.2.3.1 FAVIPIRAVIR 168
9.2.3.2 BALOXAVIR MARBOXIL 168
9.3 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 169
9.3.1 REVERSE TRANSCRIPTASE INHIBITORS 170
9.3.1.1 NUCLEOSIDE (NRTIS) 170
9.3.1.1.1 LAMIVUDINE 171
9.3.1.1.2 ABACAVIR 171
9.3.1.1.3 DIDANOSINE 171
9.3.1.1.4 OTHERS 171
9.3.1.2 NONNUCLEOSIDE (NNRTIS) 171
9.3.1.2.1 EFAVIRENZ 171
9.3.1.2.2 NEVIRAPINE 171
9.3.1.2.3 DELAVIRDINE 171
9.3.1.2.4 OTHERS 172
9.3.1.3 INTEGRASE 172
9.3.1.3.1 DOLUTEGRAVIR 172
9.3.1.3.2 ELVITEGRAVIR 172
9.3.1.3.3 RALTEGRAVIR 172
9.3.1.3.4 BICTEGRAVIR 172
9.3.1.4 NUCLEOTIDE 172
9.3.1.4.1 TENOFOVIR 173
9.3.1.4.2 OTHERS 173
9.3.1.5 INTERFERONS 173
9.3.1.5.1 ALPHA 173
9.3.1.5.2 BETA 173
9.3.1.5.3 GAMMA 174
9.3.1.6 GP41 174
9.3.1.6.1 ENFUVIRTIDE 174
9.3.1.6.2 OTHERS 174
9.3.2 PROTEASE 175
9.3.2.1 ATAZANAVIR 175
9.3.2.2 DARUNAVIR 175
9.3.2.3 LOPINAVIR 175
9.3.2.4 RITONAVIR 175
9.3.2.5 SAQUINAVIR 175
9.3.2.6 INDINAVIR 175
9.3.2.7 NELFINAVIR 176
9.3.2.8 TIPRANAVIR 176
9.3.2.9 AMPRENAVIR 176
9.4 HEPATITIS C VIRUS 176
9.4.1 NS5B POLYMERASE 177
9.4.1.1 SOFOSBUVIR 177
9.4.1.2 DASABUVIR 177
9.4.2 NS3/4A PROTEASE 178
9.4.2.1 DANOPREVIR 178
9.4.2.2 GLECAPREVIR 178
9.4.2.3 GRAZOPREVIR 178
9.4.2.4 PARITAPREVIR 178
9.4.2.5 SIMEPREVIR 178
9.4.3 NS5A PHOSPHOPROTEIN 179
9.4.3.1 LEDIPASVIR 179
9.4.3.2 VELPATASVIR 179
9.4.3.3 OMBITASVIR 179
9.4.3.4 ELBASVIR 179
9.4.3.5 DACLATASVIR 179
9.4.3.6 PIBRENTASVIR 179
9.4.4 NEURAMINIDASE 180
9.4.4.1 OSELTAMIVIR 180
9.4.4.2 ZANAMIVIR 180
9.4.4.3 PERAMIVIR 180
9.4.4.4 LANINAMIVIR 180
9.4.5 RNA POLYMERASE 180
9.4.5.1 BALOXAVIR MARBOXIL 181
9.4.5.2 FAVIPIRAVIR 181
9.4.6 MATRIX PROTEIN 2 181
9.4.6.1 RIMATIDINE 181
9.4.6.2 FAVIPIRAVIR 181
9.5 HERPES SIMPLEX VIRUS 182
9.5.1 DNA POLYMERASE UL30 183
9.5.1.1 ACICLOVIR 183
9.5.1.2 FAMCICLOVIR 183
9.5.1.3 VALACICLOVIR 183
9.5.1.4 PENCICLOVIR TRIFLURIDINE 183
9.5.1.5 BRIVUDINE 183
9.5.1.6 FOSCARNET 183
9.5.1.7 IDOXURIDINE 184
9.5.2 ENVELOPE PROTEINS 184
9.5.2.1 DOCOSANOL 184
9.5.2.2 OTHERS 184
9.6 HUMAN CYTOMEGALOVIRUS (HCMV) 184
9.6.1 GANCICLOVIR 185
9.6.2 VALGANCICLOVIR 185
9.6.3 CIDOFOVIR 185
9.6.4 FOSCARNET 185
9.6.5 FOMIVIRSEN 185
9.7 VARICELLA-ZOSTER VIRUS (VZV) 186
9.7.1 VALACICLOVIR 187
9.7.2 FAMCICLOVIR 187
9.7.3 ACICLOVIR 187
9.7.4 VIDARABINE 187
9.7.5 BRIVUDINE 187
9.8 HEPATITIS B VIRUS 187
9.8.1 ENTECAVIR 188
9.8.2 TENOFOVIR 188
9.8.3 TELBIVUDINE 188
9.8.4 TENOFOVIR ALAFENAMIDE 189
9.8.5 OTHERS 189
9.9 RESPIRATORY SYNCYTIAL VIRUS 189
9.9.1 RNA POLYMERASE 190
9.9.1.1 RIBAVIRIN 190
9.9.1.2 OTHERS 190
9.9.2 FUSION GLYCOPROTEIN 190
9.9.2.1 PALIVIZUMAB 191
9.9.2.2 OTHERS 191
9.10 CORONAVIRUS INFECTION 191
9.11 OTHERS 192
10 GLOBAL ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE 193
10.1 OVERVIEW 194
10.2 GERIATRIC 197
10.2.1 MALE 197
10.2.2 FEMALE 197
10.3 CHILD 198
10.3.1 MALE 198
10.3.2 FEMALE 199
10.4 ADULT 199
10.4.1 MALE 200
10.4.2 FEMALE 200
11 GLOBAL ANTIVIRAL DRUGS MARKET, BY PRODUCTS 201
11.1 OVERVIEW 202
11.2 ORAL 205
11.2.1 SOLID 206
11.2.1.1 TABLETS 206
11.2.1.2 CAPSULES 206
11.2.1.3 OTHERS 206
11.2.2 SEMISOLID 206
11.2.2.1 GELS 207
11.2.2.2 EMULSIONS 207
11.2.2.3 ELIXIRS 207
11.2.2.4 OTHERS 207
11.2.3 LIQUID 207
11.2.3.1 SOLUTIONS 207
11.2.3.2 SYRUPS 207
11.2.3.3 OTHERS 207
11.3 TOPICAL 208
11.3.1 SEMI-SOLID 209
11.3.1.1 CREAM 209
11.3.1.2 OINTMENT 209
11.3.1.3 GELS 209
11.3.1.4 OTHERS 209
11.3.2 LIQUID 209
11.3.2.1 SOLUTIONS 210
11.3.2.2 SUSPENSIONS 210
11.3.3 SOLID 210
11.3.3.1 POWDERS 210
11.3.3.2 SUPPOSITORIES 210
11.3.3.3 ENEMA 210
11.3.3.4 OTHERS 210
11.4 PARENTERAL 211
11.4.1 CONVENTIONAL DRUG DELIVERY FORMUALTIONS 212
11.4.1.1 SOLUTIONS 212
11.4.1.2 RECONSTITUTED/LYOPHILIZED 212
11.4.1.3 SUSPENSIONS 212
11.4.1.4 EMULSIONS 212
11.4.1.5 OTHERS 212
11.4.2 NOVEL DRUG DELIVERY FORMULATIONS 213
11.4.3 COLLOIDAL DISPERSIONS 213
11.4.4 LONG ACTING INJECTION FORMULATION 213
12 GLOBAL ANTIVIRAL DRUGS MARKET, BY DRUG TYPE 214
12.1 OVERVIEW 215
12.2 GENERIC 218
12.3 BRANDED 218
13 GLOBAL ANTIVIRAL DRUGS MARKET, BY END USER 219
13.1 OVERVIEW 220
13.2 HOSPITAL 223
13.3 SPECIALTY CENTERS 223
13.4 AMBULATORY CENTRES 224
13.5 CLINICS 224
13.6 HOME HEALTHCARE 224
13.7 OTHERS 225
14 GLOBAL ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL 226
14.1 OVERVIEW 227
14.2 HOSPITAL PHARMACY 230
14.3 RETAIL PHARMACY 230
14.4 ONLINE PHARMACY 231
15 GLOBAL ANTIVIRAL DRUGS MARKET, BY REGION 232
15.1 OVERVIEW 233
15.2 NORTH AMERICA 238
15.2.1 U.S. 261
15.2.2 CANADA 280
15.2.3 MEXICO 297
15.3 EUROPE 315
15.3.1 GERMANY 337
15.3.2 FRANCE 355
15.3.3 U.K. 372
15.3.4 HUNGARY 389
15.3.5 LITHUANIA 405
15.3.6 AUSTRIA 422
15.3.7 IRELAND 439
15.3.8 NORWAY 455
15.3.9 POLAND 472
15.3.10 ITALY 490
15.3.11 SPAIN 506
15.3.12 RUSSIA 522
15.3.13 TURKEY 539
15.3.14 NETHERLANDS 555
15.3.15 SWITZERLAND 573
15.3.16 REST OF EUROPE 591

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.